Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis A 20-year followup study

Charles D. Radis, Leslie Kahl, Gary L. Baker, Mary Chester Morgan Wasko, Joseph M. Cash, Aileen Gallatin, Bertrand L. Stolzer, Amrit K. Agarwal, Thomas A. Medsger, C. Kent Kwoh

Research output: Contribution to journalArticle

242 Citations (Scopus)

Abstract

Objective. To examine the effects of cyclophosphamide (CYC) on the development of malignancies and on the long-term survival of patients with rheumatoid arthritis (RA). Methods. We used a longitudinal cohort design in which 119 patients (76 women and 43 men) with refractory RA who were treated with oral CYC between 1968 and 1973 were compared with 119 control patients with RA (matched for age, sex, disease duration, and functional class) who were evaluated during the same time period but did not receive CYC. Results. There was increased risk of malignancy in the CYC-treated group, with 50 cancers found in 37 patients in the CYC group compared with 26 cancers in 25 of the control patients (P <0.05). The relative risk of cancer for those treated with CYC was 1.5 (95% confidence interval 0.93-5.5). Nine of the malignancies in the CYC group were bladder cancers and 19 were skin cancers, compared with no bladder cancers and 6 skin cancers in the control group. The total dose of CYC was higher in those who developed cancer, particularly in those with bladder cancer. Three of the bladder cancers occurred 14, 16, and 17 years after CYC had been discontinued. Conclusion. The risk of malignancy, particularly bladder cancer, in RA patients treated with oral CYC continues even 17 years after discontinuation of the drug.

Original languageEnglish (US)
Pages (from-to)1120-1127
Number of pages8
JournalArthritis and Rheumatism
Volume38
Issue number8
StatePublished - Aug 1995
Externally publishedYes

Fingerprint

Cyclophosphamide
Rheumatoid Arthritis
Survival
Urinary Bladder Neoplasms
Neoplasms
Skin Neoplasms
Confidence Intervals
Control Groups
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis A 20-year followup study. / Radis, Charles D.; Kahl, Leslie; Baker, Gary L.; Wasko, Mary Chester Morgan; Cash, Joseph M.; Gallatin, Aileen; Stolzer, Bertrand L.; Agarwal, Amrit K.; Medsger, Thomas A.; Kwoh, C. Kent.

In: Arthritis and Rheumatism, Vol. 38, No. 8, 08.1995, p. 1120-1127.

Research output: Contribution to journalArticle

Radis, CD, Kahl, L, Baker, GL, Wasko, MCM, Cash, JM, Gallatin, A, Stolzer, BL, Agarwal, AK, Medsger, TA & Kwoh, CK 1995, 'Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis A 20-year followup study', Arthritis and Rheumatism, vol. 38, no. 8, pp. 1120-1127.
Radis, Charles D. ; Kahl, Leslie ; Baker, Gary L. ; Wasko, Mary Chester Morgan ; Cash, Joseph M. ; Gallatin, Aileen ; Stolzer, Bertrand L. ; Agarwal, Amrit K. ; Medsger, Thomas A. ; Kwoh, C. Kent. / Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis A 20-year followup study. In: Arthritis and Rheumatism. 1995 ; Vol. 38, No. 8. pp. 1120-1127.
@article{77a30b966dc34eaaa0f29ef9b177fec8,
title = "Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis A 20-year followup study",
abstract = "Objective. To examine the effects of cyclophosphamide (CYC) on the development of malignancies and on the long-term survival of patients with rheumatoid arthritis (RA). Methods. We used a longitudinal cohort design in which 119 patients (76 women and 43 men) with refractory RA who were treated with oral CYC between 1968 and 1973 were compared with 119 control patients with RA (matched for age, sex, disease duration, and functional class) who were evaluated during the same time period but did not receive CYC. Results. There was increased risk of malignancy in the CYC-treated group, with 50 cancers found in 37 patients in the CYC group compared with 26 cancers in 25 of the control patients (P <0.05). The relative risk of cancer for those treated with CYC was 1.5 (95{\%} confidence interval 0.93-5.5). Nine of the malignancies in the CYC group were bladder cancers and 19 were skin cancers, compared with no bladder cancers and 6 skin cancers in the control group. The total dose of CYC was higher in those who developed cancer, particularly in those with bladder cancer. Three of the bladder cancers occurred 14, 16, and 17 years after CYC had been discontinued. Conclusion. The risk of malignancy, particularly bladder cancer, in RA patients treated with oral CYC continues even 17 years after discontinuation of the drug.",
author = "Radis, {Charles D.} and Leslie Kahl and Baker, {Gary L.} and Wasko, {Mary Chester Morgan} and Cash, {Joseph M.} and Aileen Gallatin and Stolzer, {Bertrand L.} and Agarwal, {Amrit K.} and Medsger, {Thomas A.} and Kwoh, {C. Kent}",
year = "1995",
month = "8",
language = "English (US)",
volume = "38",
pages = "1120--1127",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis A 20-year followup study

AU - Radis, Charles D.

AU - Kahl, Leslie

AU - Baker, Gary L.

AU - Wasko, Mary Chester Morgan

AU - Cash, Joseph M.

AU - Gallatin, Aileen

AU - Stolzer, Bertrand L.

AU - Agarwal, Amrit K.

AU - Medsger, Thomas A.

AU - Kwoh, C. Kent

PY - 1995/8

Y1 - 1995/8

N2 - Objective. To examine the effects of cyclophosphamide (CYC) on the development of malignancies and on the long-term survival of patients with rheumatoid arthritis (RA). Methods. We used a longitudinal cohort design in which 119 patients (76 women and 43 men) with refractory RA who were treated with oral CYC between 1968 and 1973 were compared with 119 control patients with RA (matched for age, sex, disease duration, and functional class) who were evaluated during the same time period but did not receive CYC. Results. There was increased risk of malignancy in the CYC-treated group, with 50 cancers found in 37 patients in the CYC group compared with 26 cancers in 25 of the control patients (P <0.05). The relative risk of cancer for those treated with CYC was 1.5 (95% confidence interval 0.93-5.5). Nine of the malignancies in the CYC group were bladder cancers and 19 were skin cancers, compared with no bladder cancers and 6 skin cancers in the control group. The total dose of CYC was higher in those who developed cancer, particularly in those with bladder cancer. Three of the bladder cancers occurred 14, 16, and 17 years after CYC had been discontinued. Conclusion. The risk of malignancy, particularly bladder cancer, in RA patients treated with oral CYC continues even 17 years after discontinuation of the drug.

AB - Objective. To examine the effects of cyclophosphamide (CYC) on the development of malignancies and on the long-term survival of patients with rheumatoid arthritis (RA). Methods. We used a longitudinal cohort design in which 119 patients (76 women and 43 men) with refractory RA who were treated with oral CYC between 1968 and 1973 were compared with 119 control patients with RA (matched for age, sex, disease duration, and functional class) who were evaluated during the same time period but did not receive CYC. Results. There was increased risk of malignancy in the CYC-treated group, with 50 cancers found in 37 patients in the CYC group compared with 26 cancers in 25 of the control patients (P <0.05). The relative risk of cancer for those treated with CYC was 1.5 (95% confidence interval 0.93-5.5). Nine of the malignancies in the CYC group were bladder cancers and 19 were skin cancers, compared with no bladder cancers and 6 skin cancers in the control group. The total dose of CYC was higher in those who developed cancer, particularly in those with bladder cancer. Three of the bladder cancers occurred 14, 16, and 17 years after CYC had been discontinued. Conclusion. The risk of malignancy, particularly bladder cancer, in RA patients treated with oral CYC continues even 17 years after discontinuation of the drug.

UR - http://www.scopus.com/inward/record.url?scp=0029099946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029099946&partnerID=8YFLogxK

M3 - Article

C2 - 7639809

AN - SCOPUS:0029099946

VL - 38

SP - 1120

EP - 1127

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 8

ER -